Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial - Akhondzadeh, Shahin; Mohammadi, Neyousha; Noroozian, Maryam; Karamghadiri, Naregs; Ghoreishi, Aboulfazl; Jamshidi, Amir-Hossein; Forghani, Saeedeh (Schizophrenia research, 2009)
Keywords: 5-HT3; Adult; Adult and adolescent clinical studies; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Biological and medical sciences; Case-Control Studies; Chronic Disease; Cognition Disorders - diagnosis; Cognition Disorders - drug therapy; Cognition Disorders - psychology; Cognitive impairments; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medical sciences; Neuropsychological Tests; Ondansetron; Ondansetron - administration & dosage; Ondansetron - adverse effects; Psychiatric Status Rating Scales; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Risperidone - administration & dosage; Schizophrenia; Schizophrenia - drug therapy; Schizophrenic Psychology; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - adverse effects; Young Adult; Schizophrenia; Cognitive impairments; Ondansetron; 5-HT3; Psychosis; Human; Cognitive disorder; Serotonin antagonist; 5-HT3 Serotonine receptor; Double blind study; Controlled therapeutic trial; Antiemetic